XWPharma: XWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

REDWOOD CITY, Calif. and WUHAN, China, May 19, 2021 (GLOBE NEWSWIRE) -- XWPharma Ltd. today announced that data from clinical research of XW10172, a new chemical entity (NCE) in development for the treatment of sleep disorders associated with neurodegenerative diseases and narcolepsy, has been accepted for poster and oral presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting, which will be held virtually from June 10-13, 2021. Details of the poster and presentation are as follows: Title: Clinical Pharmacokinetics of XW10172 for Once-Nightly Therapy in Patients with Narcolepsy or Sleep Disorders in Patients with Neurodegenerative Diseases Abstract number: 501 Presenter: Dr. Daniel Canafax, Chief Medical Officer, XWPharma Ltd. Session Name: Innovation in the Assessment and Management of Central Hypersomnia Session Details: June 13, 12:52 PM Eastern Daylight Time The abstract and ...Full story available on Benzinga.com